Business
Voyageur Pharmaceuticals Ltd. Announces up to $1,725,000 Private Placement Financing
(TheNewswire) Calgary, Alberta – TheNewswire - Apr...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces up to $1,725,000 Private Placement Financing\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta –\n \n \n TheNewswire -\n \n \n April 13\n \n \n th\n \n \n 2021\n \n \n –\n \n \n Voyageur Pharmaceuticals\nLtd.\n \n \n (\n \n \n TSXV\n \n \n :\n \n \n VM\n \n \n )\n \n \n USA\n \n \n (OTC\n \n \n :\n \n \n \n VYYRF)\n \n \n \n (the “Company” or\n“Voyageur”),\n \n \n is pleased to announce a\nproposed non-brokered private placement financing of up to 11,500,000\nunits, for gross proceeds of up to $1,725,000 (the\n\"Offering\").  Under the Offering, the Company expects to\nraise up to $1,500,000, but has approved up to $1,725,000 to give the\nCompany an option to increase the Offering by up to 15% to cover\nover-allocations, if any.  Pricing is as follows: A \"Common\nUnit\" priced at $0.15 where each Common Unit is comprised of one\ncommon share in the capital of the Company (each, a \"Common\nShare\") and one full Common Share purchase warrant, exercisable\nat $0.30 for twenty-four months from closing.  The Company will also\noffer \"Flow-Through Units\" priced at $0.18 per Flow-Through\nUnit and comprising one Common Share issued on a flow-through basis\npursuant to the\n \n \n Income Tax\nAct\n \n \n (Canada) and one Common Share purchase\nwarrant, exercisable at $0.40 for a period of twenty-four months from\nclosing.\n \n \n \n \n \n \n \n \n The net proceeds received by Voyageur from the\nOffering will be used to advance Voyageur’s project:\n \n \n \n \n PEA/Pre-feasibilty Study/FC Development                    \n      $500,000\n \n \n \n \n Sales and Marketing Initiatives                         \n        $150,000\n \n \n \n \n Product Roll Out & Testing                         \n                $300,000\n \n \n \n \n General Corporate Use                               \n          $350,000\n \n \n \n \n FDA/International Reg...